Role of prostaglandins on the renal effects of angiotensin and interstitial pressure during volume expansion.
This study was undertaken to determine, in anesthetized dogs, the role of renal prostaglandins (PG) in mediating the natriuretic response to increased renal interstitial hydrostatic pressure (RIHP) during extracellular volume expansion (ECVE) with isotonic saline. It was also determined if the intrarenal angiotensin II (ANG II) effects during ECVE are potentiated by the inhibition of PG synthesis. ECVE induced similar elevations of RIHP, natriuresis, and fractional lithium excretion in dogs treated (n = 7) and not treated with a PG synthesis inhibitor (n = 5). In other experimental groups, the effects of the intrarenal maintenance of ANG II levels (n = 6) by infusing captopril and ANG II into the right renal artery were compared with those induced by the simultaneous infusion of captopril, ANG II, and a PG synthesis inhibitor (n = 6). In response to ECVE, renal blood flow and glomerular filtration rate were similar in both kidneys when ANG II levels were maintained constant and were significantly higher in the left kidney when ANG II levels were maintained constant and PG synthesis was inhibited in the right kidney. However, when compared with the left kidney, the ECVE-induced increments of natriuresis and RIHP in the right kidney were reduced by the same magnitude when intrarenal ANG II was maintained constant with (36 and 53%, respectively) and without (40 and 54%, respectively) the simultaneous PG synthesis inhibition. Our results indicate that during ECVE, renal PGs do not play an important role in mediating the RIHP-induced increments in natriuresis and decrements in proximal sodium reabsorption. (ABSTRACT TRUNCATED AT 250 WORDS)
Pinilla
J M
JM
Departamento de Fisiologia, Facultad de Medicina, Murcia, Spain.
Alberola
A
A
González
J D
JD
Quesada
T
T
Salazar
F J
FJ
D000804:Angiotensin II / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D002216:Captopril / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D005110:Extracellular Space / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006874:Hydrostatic Pressure; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D008094:Lithium / Q000652:urine; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000502:physiology*; D012965:Sodium Chloride / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D016861:Cyclooxygenase Inhibitors; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D000804:Angiotensin II; D012965:Sodium Chloride; D008094:Lithium; D002216:Captopril